CTL019 Out of Specification MAP for ALL or DLBCL Patients
Recruiting in Palo Alto (17 mi)
+147 other locations
Age: < 65
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Novartis Pharmaceuticals
No Placebo Group
Approved in 3 jurisdictions
Trial Summary
What is the purpose of this trial?Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.
Eligibility Criteria
Participant Groups
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Emory University School of Medicine Emory University (12)Atlanta, GA
The Ohio State University Comprehensive Cancer Center Ohio State UMC James Cancer CtColumbus, OH
Children's Healthcare of Atlanta Cellular Therapies LabAtlanta, GA
Memorial Sloan KetteringNew York, NY
More Trial Locations
Loading ...
Who is running the clinical trial?
Novartis PharmaceuticalsLead Sponsor